Liao Yuxiang, Liu Bo, Jin Chen, Liao Xinbin, Zhang Zhiping
Department of Neurosurgery, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Changsha, 410008, Hunan Province, People's Republic of China.
J Mol Neurosci. 2022 Dec;72(12):2413-2424. doi: 10.1007/s12031-022-02083-x. Epub 2022 Nov 30.
In this study, we intend to identify key immune-related genes (IRGs) in gliomas using the TCGA and GTEx databases. Following collection of the RNA-seq data of lower-grade glioma (LGG) and glioblastoma (GBM) patients from the TCGA and GTEx databases, the differentially expressed IRGs (DE-IRGs) were screened. The ESTIMATE algorithm was utilized to evaluate StromalScore and ImmuneScore of LGG and GBM samples and a multifactorial Cox risk model was constructed to identify the related risk genes. The core IRGs of LGG and GBM were screened through a PPI network, followed by exploration of their correlation with glioma prognosis. The relationship between IRGs and immune cells in LGG and GBM was detected. In vitro assays were performed to detect the effect of CXCL9 on glioma cell development. We screened 403 and 492 DE-IRGs in LGG and GBM. StromalScore and ImmuneScore were related to overall survival in LGG, but not in GBM. CXCL9 was identified as a core gene in LGG and GBM and shared association with the prognosis of gliomas. Furthermore, a correlation was found between CXCL9 and immune infiltration of LGG and GBM. Glioma cell proliferation and invasion could be inhibited by silencing of CXCL9. Overall, CXCL9 is correlated to the prognosis of glioma patients and may accelerate glioma development via immune regulation.
在本研究中,我们打算利用TCGA和GTEx数据库鉴定神经胶质瘤中的关键免疫相关基因(IRG)。从TCGA和GTEx数据库收集低级别神经胶质瘤(LGG)和胶质母细胞瘤(GBM)患者的RNA测序数据后,筛选出差异表达的IRG(DE-IRG)。利用ESTIMATE算法评估LGG和GBM样本的基质评分和免疫评分,并构建多因素Cox风险模型以鉴定相关风险基因。通过蛋白质-蛋白质相互作用(PPI)网络筛选LGG和GBM的核心IRG,随后探究它们与神经胶质瘤预后的相关性。检测LGG和GBM中IRG与免疫细胞之间的关系。进行体外实验以检测CXCL9对神经胶质瘤细胞发育的影响。我们在LGG和GBM中分别筛选出403个和492个DE-IRG。基质评分和免疫评分与LGG的总生存期相关,但与GBM无关。CXCL9被鉴定为LGG和GBM中的核心基因,且与神经胶质瘤的预后相关。此外,发现CXCL9与LGG和GBM的免疫浸润之间存在相关性。沉默CXCL9可抑制神经胶质瘤细胞的增殖和侵袭。总体而言,CXCL9与神经胶质瘤患者的预后相关,并且可能通过免疫调节加速神经胶质瘤的发展。